US Patent 5,633,008: Scope, Claims, Expiration, and Nicotine Patch Patent Landscape

US Patent 5,633,008 covers a specific 16-hour nicotine transdermal treatment regimen, not nicotine patches generally. Its claims require morning application, use during waking hours, removal before sleep, and, in narrower claims, defined nicotine delivery rates, flux limits, and reservoir activity characteristics. The patent issued on May 27, 1997, and its enforceable term has expired. It therefore does not create a current U.S. barrier to generic, OTC-monograph, or prescription nicotine patch products.

What does US Patent 5,633,008 protect?

The patent protects a method of administering nicotine through a transdermal device for approximately 16 hours. Claim 1 is the controlling independent claim. It requires all of the following elements:

An individual in need of nicotine administration.
Application of a nicotine-containing transdermal device upon waking.
A nicotine reservoir containing enough nicotine to maintain useful transdermal flux for at least 16 hours.
Continued skin contact during waking hours.
Removal before sleep.

The claim is directed to a dosing regimen combined with a transdermal delivery device. It does not broadly claim every nicotine patch, every nicotine formulation, or every method of smoking cessation.

The patent's core distinction is the use of a daytime-only patch. The regimen avoids continuous overnight nicotine exposure, which was associated with sleep disturbance and vivid dreams in some nicotine replacement therapy users.

What is the claim hierarchy?

Claim	Additional limitation	Practical scope
1	Morning application, at least 16-hour useful flux, waking-hour use, removal before sleep	Broadest claim
2	Application-to-removal period of about 16 hours	Defines the typical daytime regimen
3	Administration rate of approximately 250 to 4,000 micrograms per hour	Limits dose delivery
4	Average flux no greater than 200 micrograms/cm²/hour	Adds an area-normalized flux ceiling
5	Average flux no greater than 120 micrograms/cm²/hour	Narrower flux limitation
6	Rate maintained substantially constant during a substantial portion of treatment	Requires controlled delivery
7	Subsaturated reservoir, nicotine activity below 1.0, and activity decline of no more than 75%	Protects reservoir behavior
8	Initial nicotine activity no greater than 0.5	Further narrows claim 7
9	Activity decline of no more than 25% over 16 hours	Most restrictive reservoir claim

Claims 2 through 9 depend on claim 1. A product or method that does not satisfy claim 1 cannot infringe the dependent claims.

How should claim 1 be construed?

Claim 1 contains both regimen and device limitations. A patch must not merely contain nicotine. It must have a reservoir with sufficient nicotine capacity to maintain a useful flux for at least 16 hours.

"Upon waking" and "before sleep"

These limitations create a defined temporal regimen. A product used continuously for 24 hours does not automatically satisfy the claimed removal-before-sleep requirement. Likewise, a patch applied at an arbitrary time would raise a claim-construction issue because the claim expressly requires application upon waking.

The terms are functional and contextual rather than fixed clock times. Application at 7:00 a.m. and removal at approximately 11:00 p.m. would fit the ordinary 16-hour regimen. Application at noon and removal at 4:00 a.m. would be less consistent with the claim because removal would occur after the normal sleep period.

"Useful transdermal flux"

The phrase is not defined solely by a fixed numerical rate in claim 1. The dependent claims provide numerical delivery ranges, but claim 1 uses a functional standard. A technical infringement analysis would examine patch design, in vitro release data, in vivo delivery data, and whether the reservoir remains capable of delivering nicotine over the claimed period.

Reservoir versus matrix construction

The claims repeatedly refer to a nicotine reservoir. That language may distinguish a reservoir-type system from some matrix systems, depending on the patent specification and the specific construction adopted by a court. A matrix patch that contains nicotine distributed through a polymer may not be equivalent to a discrete reservoir in every case.

The distinction is important because modern nicotine patches commonly use matrix designs, while older transdermal systems included reservoir structures, rate-controlling membranes, adhesives, and backing layers.

What do claims 3 through 6 protect?

Claims 3 through 6 add quantitative delivery restrictions.

Claim 3 covers an administration rate of approximately 250 to 4,000 micrograms per hour during a substantial portion of the treatment period. This range spans low-dose and higher-dose nicotine patch products.

Claims 4 and 5 limit average flux by patch area:

Claim 4: no more than 200 micrograms/cm²/hour.
Claim 5: no more than 120 micrograms/cm²/hour.

The claims distinguish total administration rate from flux. Administration rate is measured in micrograms per hour. Flux is measured by area, in micrograms per square centimeter per hour. A large patch and a small patch could deliver the same total dose while producing different flux values.

Claim 6 requires the administration rate to remain substantially constant during a substantial portion of the administration period. This limitation favors controlled-release systems and may exclude products with a pronounced initial burst followed by rapid decline, depending on the data and claim construction.

What do claims 7 through 9 protect?

Claims 7 through 9 focus on nicotine thermodynamic activity and reservoir loading.

A subsaturated reservoir has a nicotine activity below 1.0. In simplified terms, the reservoir contains less nicotine than the maximum amount that could be dissolved or maintained under the relevant formulation conditions. The claim does not require the reservoir to be saturated. It requires sufficient initial loading to prevent excessive loss of nicotine activity during the 16-hour period.

Claim	Activity requirement
7	Activity below 1.0; decline limited to 75% or less
8	Initial activity no greater than 0.5
9	Decline limited to 25% or less

These claims are formulation- and performance-dependent. A party evaluating potential exposure would need formulation composition, initial loading, activity measurements, reservoir equilibrium data, and post-use analysis.

The limitations may be difficult to establish from public product labeling alone. They generally require technical testing or discovery. They also create design-around opportunities. A manufacturer could use a different nicotine concentration, a matrix rather than a reservoir, a different delivery mechanism, or a profile that does not satisfy the specified activity conditions.

When did US Patent 5,633,008 expire?

US Patent 5,633,008 issued May 27, 1997. Its term ran under the 20-year framework measured from the applicable nonprovisional filing or priority date under 35 U.S.C. § 154. Public U.S. patent records identify the patent as expired, with the term ending in the 2014 period. The patent is therefore not an enforceable U.S. exclusion right today.[1][2]

Event	Date or status
Patent issued	May 27, 1997
Statutory term framework	20 years from applicable filing date
Effective U.S. status	Expired
Current enforceability	None
Current generic-launch blocking effect	None

The expiration applies to the patent's claims. It does not automatically eliminate other patents covering a particular nicotine patch, adhesive, manufacturing process, packaging system, or brand.

What is the Orange Book status of US Patent 5,633,008?

US Patent 5,633,008 is not a current Orange Book barrier to nicotine patch products. Orange Book listing is tied to patents submitted for approved drug products under FDA regulations. A patent's existence or historical relationship to a nicotine patch does not itself establish a current Orange Book listing.[3]

Nicotine replacement products also occupy a mixed regulatory position:

Many nicotine patches are marketed under FDA's OTC nicotine replacement therapy framework.
Prescription nicotine patches may be associated with approved NDA products, although commercial status changes over time.
OTC-monograph marketing does not depend on an ANDA applicant challenging a listed patent in the same way as a conventional prescription generic product.
An expired method patent cannot support a current Paragraph IV exclusion period.

Are there Paragraph IV challenges to this patent?

There is no current Paragraph IV risk associated with US Patent 5,633,008 because the patent has expired. A Paragraph IV certification is relevant when an ANDA applicant seeks approval before expiration of a listed patent. The patent's expired status removes the statutory delay and litigation leverage that would have existed during its enforceable term.[4]

Historical ANDA or patent disputes involving nicotine patches could have concerned other patents, including formulation, adhesive, delivery-rate, or device patents. Those disputes would not revive US Patent 5,633,008.

What patent landscape surrounds 16-hour nicotine patches?

The relevant landscape has four technical groups.

Earlier transdermal nicotine patents

Earlier patents addressed the basic concept of delivering nicotine through the skin, including nicotine reservoirs, permeation enhancers, adhesives, backing layers, and controlled-release systems. Those patents established the technical foundation for nicotine patches but have generally expired because they date from the 1980s and early 1990s.

Regimen patents

US Patent 5,633,008 is primarily a regimen patent. Its commercial concept is the daytime, approximately 16-hour patch rather than a continuous 24-hour system.

A regimen patent can be commercially important while active because a product label, patient instructions, and ordinary use can directly map to the claimed steps. Once expired, however, the regimen becomes available for unrestricted use unless another active patent covers the product.

Formulation and reservoir patents

Other patent families may cover:

Nicotine salts and free-base nicotine systems.
Ethanol, water, glycols, and permeation enhancers.
Supersaturated or subsaturated nicotine reservoirs.
Rate-controlling membranes.
Polymer matrices.
Pressure-sensitive adhesives.
Residual nicotine management.
Patch adhesion during perspiration or bathing.
Reduced skin irritation.

Claims 7 through 9 of US 5,633,008 belong to this formulation-performance category, but they are narrower than a generic claim to nicotine in a transdermal patch.

Manufacturing and device patents

Manufacturing IP may cover coating, laminating, die-cutting, pouching, reservoir filling, solvent removal, and quality-control methods. Those rights can remain relevant to freedom-to-operate even when a core use patent has expired.

How does US Patent 5,633,008 compare with 24-hour nicotine patch protection?

Issue	16-hour regimen under US 5,633,008	24-hour patch
Application	Upon waking	Often morning or specified daily interval
Removal	Before sleep	Typically the next day
Claimed duration	About 16 hours	Approximately 24 hours
Main clinical rationale	Limits overnight exposure	Maintains continuous nicotine replacement
Patent relevance today	Expired	Depends on separate product patents
Current launch barrier from 5,633,008	None	None

A 24-hour patch used continuously would generally not practice the full claimed daytime regimen because it would remain in place during sleep. A 16-hour patch used from waking until bedtime is the direct commercial embodiment of the claimed method.

What is the current litigation and settlement status?

US Patent 5,633,008 has no present litigation significance because its claims are expired. There is no current infringement remedy, injunction risk, or Paragraph IV settlement value attributable to this patent.

Historical disputes involving nicotine replacement products may have addressed other patents or regulatory issues. A settlement involving a separate nicotine patch patent would not extend the term of US Patent 5,633,008 and would not create new exclusivity for its expired claims.

Which companies face competitive risk from this patent estate?

The patent does not create current competitive risk for manufacturers of nicotine patches. The commercial landscape includes branded and private-label products marketed through OTC nicotine replacement channels, prescription products where available, and contract manufacturers supplying pharmacy and retail brands.

Competitive differentiation now depends more heavily on:

Patch size and wear time.
Adhesion.
Skin tolerability.
Nicotine dose.
Retail distribution.
OTC compliance.
Manufacturing cost.
Brand recognition.
Packaging and consumer instructions.

The expired patent may still be relevant in historical diligence because it explains the intellectual-property basis for a daytime nicotine patch. It is not a current royalty or launch constraint.

What generic launch scenarios exist?

OTC-monograph launch

A compliant nicotine patch can be marketed under the applicable FDA OTC framework without relying on an active patent term for this regimen. The manufacturer must satisfy the monograph, labeling, quality, manufacturing, and postmarket requirements.

ANDA launch

If a product is positioned as a generic version of an approved prescription nicotine patch, the applicant may use the ANDA pathway. Because US Patent 5,633,008 is expired, it cannot support a Paragraph IV delay.

505(b)(2) launch

A modified nicotine transdermal product with a different delivery profile, dosage form, or clinical labeling could use a 505(b)(2) strategy where appropriate. The relevant regulatory exclusivity and patent analysis would focus on the reference product and any other listed patents, not on US Patent 5,633,008.

Key Takeaways

US Patent 5,633,008 covers a daytime nicotine patch regimen applied upon waking and removed before sleep.
Claim 1 requires a nicotine reservoir capable of maintaining useful flux for at least 16 hours.
Claims 3 through 6 add administration-rate, flux, and delivery-consistency limitations.
Claims 7 through 9 cover subsaturated reservoir activity and limits on activity decline.
The patent issued May 27, 1997, and is expired.
It is not a current Orange Book or Paragraph IV barrier.
No biosimilar analysis applies because nicotine is a small molecule, not a biologic.
Current freedom-to-operate analysis must examine separate formulation, adhesive, device, manufacturing, and regulatory rights.
The patent has historical value for understanding 16-hour nicotine patch development but no present exclusionary value.

FAQs About US Patent 5,633,008

Does US Patent 5,633,008 cover all nicotine patches?

No. It covers a defined method using a transdermal nicotine reservoir, morning application, waking-hour use, and removal before sleep. It does not cover every nicotine patch or every nicotine formulation.

Can a 24-hour nicotine patch infringe US Patent 5,633,008?

A continuously worn 24-hour patch would not ordinarily satisfy the claim's requirement that the device be removed before sleep. Other patents could still be relevant.

Does the patent cover nicotine gum, lozenges, or inhalers?

No. The claims require transdermal administration through a device applied to the skin. Oral and inhaled nicotine products fall outside the claimed delivery route.

Is a subsaturated nicotine reservoir required for every claim?

No. The subsaturated-reservoir limitation appears only in claims 7 through 9. Claims 1 through 6 do not expressly require a subsaturated reservoir, although claim 1 requires a nicotine reservoir.

Can a company rely on patent expiration to avoid FDA requirements?

No. Patent expiration removes the patent exclusion right. It does not remove FDA requirements governing OTC-monograph compliance, NDA approval, ANDA approval, manufacturing quality, labeling, or product safety.

References

United States Patent No. 5,633,008, Transdermal nicotine administration, issued May 27, 1997.
United States Code, 35 U.S.C. § 154, patent term.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
United States Code, 21 U.S.C. § 355(j), abbreviated new drug applications and patent certifications.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	161734	⤷ Start Trial
Australia	3852189	⤷ Start Trial
Australia	3913695	⤷ Start Trial
Australia	4491193	⤷ Start Trial
Australia	630614	⤷ Start Trial
Australia	666208	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,633,008

Summary for Patent: 5,633,008